Is King Charles Cancer-Free? Monarch Reportedly Undergoing 'Very Expensive' Experimental RNA Treatment

King Charles has reportedly been undergoing a 'cutting-edge' and 'very, very expensive' course of cancer treatment combining immunotherapy with experimental RNA drugs, a royal editor claimed in London on 30 April, raising fresh questions over the monarch's long‑term prognosis and how far his health has now improved.

The news came after more than two years of guarded updates from Buckingham Palace, which announced in 2024 that King Charles had been diagnosed with an undisclosed form of cancer. At the time, officials declined to name the type or stage of the disease, saying only that it had been detected early and that the King would continue with a reduced public schedule while receiving treatment under medical supervision.

Speaking on the Daily Beast podcast at the end of the King and Queen Camilla's four‑day visit to the United States, royal editor Tom Sykes said there was now quiet optimism within senior circles about how well the monarch has responded. According to Sykes, the 77‑year‑old sovereign has been treated with 'an incredibly novel and very, very expensive combination of immunotherapy and RNA drugs — absolutely cutting‑edge experimental stuff.'

None of those details has been confirmed by the Palace, so they should be treated with some caution.

Sykes went further, saying doctors were 'incredibly impressed at how the treatment has worked' and that insiders believed there was 'a great deal of optimism [Charles] can carry on for many, many years hence.' His comments followed a visibly demanding trip to the US, during which the King packed in a string of engagements and, by Sykes' account, appeared 'energised' rather than exhausted.

King Charles Cancer Treatment: From Public Diagnosis To 'Precautionary' Phase

For context, King Charles disclosed his cancer diagnosis publicly in early 2024, an unusually frank admission for a British monarch. The revelation prompted a flurry of speculation about succession and the role of Prince William, but the Palace insisted the King remained 'wholly positive' about his treatment.

Since then, information has been released sparingly. In a pre‑recorded message for Channel 4's Stand Up To Cancer broadcast in December 2025, the King said an early diagnosis and 'effective intervention' meant his schedule of treatment could be reduced in the new year. He called that moment 'a personal blessing' and a testament to advances in cancer care, adding that he hoped his experience might 'give encouragement to the 50% of us who will be diagnosed with the illness at some point in our lives.'

Even then, the Palace avoided the word 'remission.' A spokesperson instead said the King had 'responded exceptionally well to treatment,' and that his doctors were moving his care into a 'precautionary phase,' with ongoing monitoring to 'protect and prioritise his continued recovery.' In other words, better, but not finished.

Against that careful language, Sykes' talk of experimental RNA therapies inevitably feels bolder than anything officials have endorsed. RNA‑based cancer drugs remain largely at the trial stage and, if his account is right, it would place the King among a small, highly resourced group of patients with access to the most advanced options on offer.

Nothing in the Palace's public statements confirms those specifics, and there has been no independent medical verification.

King Charles Cancer-Free? Monarch Opens Up On Side Effects

Speculation about whether King Charles is now effectively cancer‑free has grown louder as he has resumed more public engagements and overseas travel. There is, however, no formal confirmation that the disease has gone or that it ever reached remission, and without a medical bulletin from his team, any definitive claims are guesswork.

What is clear is that the King has begun to speak more candidly about the practical realities of treatment. During a visit to Guy's Cancer Centre in London on 11 May, to mark the 300th anniversary of Guy's Hospital and hear about new research with King's College London, he sat down with patients and clinicians in what was billed as a working engagement but at times felt more personal.

When patient Raymond Burgess explained that chemotherapy left him with a lingering bad taste in his mouth, the monarch did not reach for platitudes. 'It's an awful sort of metallic taste,' he replied, according to The Telegraph. 'It doesn't exactly help with eating.' For a King who has spent decades cultivating reserve, that small admission carried its own weight.

Staff at the centre also showed him how artificial intelligence and surgical robots are being used in modern cancer care, a neat symmetry with the whispers about his own 'novel' treatment. The Palace did not link his visit to any specific drugs or clinical trials, and there was no further comment on RNA therapies.

Behind the scenes, the King's illness continues to intersect awkwardly with royal family tensions. Sykes has reported that King Charles and Prince William remain divided over how to handle Prince Harry, with the King privately inclined towards some form of reconciliation while the Prince of Wales is said to be more unyielding. If the monarch's health is indeed improving, it may strengthen his hand in those debates by reducing the immediate pressure to prepare for a transition.